EKF Diagnostics Holdings plc (LON:EKF - Get Free Report) shares dropped 7.4% on Friday . The company traded as low as GBX 25 ($0.34) and last traded at GBX 25 ($0.34). Approximately 166,070 shares traded hands during mid-day trading, a decline of 66% from the average daily volume of 483,755 shares. The stock had previously closed at GBX 27 ($0.36).
EKF Diagnostics Price Performance
The company has a market cap of £111.12 million, a price-to-earnings ratio of 23.27 and a beta of 0.57. The company has a 50-day simple moving average of GBX 21.85 and a 200-day simple moving average of GBX 23.88. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.77 and a current ratio of 4.60.
EKF Diagnostics (LON:EKF - Get Free Report) last released its quarterly earnings data on Tuesday, March 25th. The company reported GBX 1.38 ($0.02) earnings per share (EPS) for the quarter. EKF Diagnostics had a return on equity of 7.03% and a net margin of 9.37%. As a group, research analysts predict that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current year.
Insider Transactions at EKF Diagnostics
In other news, insider Gavin T. Jones acquired 50,000 shares of EKF Diagnostics stock in a transaction dated Tuesday, March 25th. The shares were acquired at an average cost of GBX 22 ($0.30) per share, with a total value of £11,000 ($14,765.10). Corporate insiders own 5.24% of the company's stock.
About EKF Diagnostics
(
Get Free Report)
EKF is an AIM-listed global diagnostics business focussed on:
● Point-of-Care analysers in the key areas of Hematology and Diabetes
● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider EKF Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EKF Diagnostics wasn't on the list.
While EKF Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
